key: cord-0700480-g1o4t8ps authors: Hansen, Frederick; Meade-White, Kimberly; Clancy, Chad; Rosenke, Rebecca; Okumura, Atsushi; Hawman, David W.; Feldmann, Friederike; Kaza, Benjamin; Jarvis, Michael A.; Rosenke, Kyle; Feldmann, Heinz title: SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract date: 2022-02-22 journal: Cell Rep DOI: 10.1016/j.celrep.2022.110515 sha: a48648a3723a9d40e6e94071a183bfdd1790c5ed doc_id: 700480 cord_uid: g1o4t8ps Human cases of SARS-CoV-2 reinfection have been documented throughout the pandemic but are likely underreported. In the current study, we used the Syrian hamster SARS-CoV-2 model to assess reinfection with homologous WA1 and heterologous B.1.1.7 (alpha) and B.1.351 (beta) SARS-CoV-2 variants over time. Upon primary infection with SARS-CoV-2 WA1, hamsters rapidly developed a strong and long-lasting humoral immune response. Following reinfection with homologous and heterologous SARS-CoV-2 variants, this immune response protected hamsters from clinical disease, virus replication in the lower respiratory tract and acute lung pathology. However, reinfection led to SARS-CoV-2 replication in the upper respiratory tract with the potential for virus shedding. Our findings indicate that reinfection results in restricted SARS-CoV-2 replication despite substantial levels of humoral immunity, denoting the potential for transmission through reinfected asymptomatic individuals. are likely underreported. In the current study, we used the Syrian hamster SARS-CoV-2 model 23 to assess reinfection with homologous WA1 and heterologous B.1.1.7 (alpha) and B. been reported from many countries since the beginning of the pandemic; however, whether 47 these cases represent real reinfection events has been difficult to verify (Prevention, 2021a, 48 Boyton and Altmann, 2021 ). An understanding of the dimension of reinfection resulting in viral 49 shedding and the effect of prior immunity on acute disease development are important from a 50 public health management perspective. 51 The first confirmation of reinfection by genomic sequencing was reported from Hong Kong in 52 August 2020, with the patient experiencing an asymptomatic reinfection with a variant from a 53 different clade 142 days after the initial symptomatic infection . Since then, hamsters were monitored for clinical signs daily and oral swabs were taken at 3 and 5 DPI (peak 136 virus shedding) for virology. Three animals were euthanized at 5 DPI (peak lung pathology) to 137 establish a baseline for virology and pathology of the primary WA1 infection. The remaining 138 infected hamsters (n=38) were allocated to three groups that were allowed to recover for 139 either 14 (Group 1, n=9), 49 (Group 2, n=12) or 152 (Group 3, n=17) DPI before reinfection with 140 WA1 was performed as described above (Figure 2A The heterologous reinfection study was designed to determine the reinfection potential with 311 distinct variants, especially VOCs of high public health concern. First, the acute infection models A. 10^3 TCID 50 Oral Swabs Necropsy (Baseline) Oral Swabs Necropsy (Baseline) Genomic evidence for reinfection with SARS-CoV-2: a case study COVID-19 re-infection by a phylogenetically distinct SARS-610 coronavirus-2 strain confirmed by whole genome sequencing Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a 614 Phylogenetically Distinct Strain Robust neutralizing 618 antibodies to SARS-CoV-2 infection persist for months Antibody resistance of SARS-CoV-2 622 variants B.1.351 and B.1.1.7 Director-General's opening remarks at the media briefing on COVID-19 WHO. 2021. Coronavirus (COVID-2019) Dashboard [Online & 630 ZHANG, Y. Z. 2020. A new coronavirus associated with human respiratory disease in China Serum Neutralizing Activity 635 Elicited by mRNA-1273 Vaccine Severe reinfection with South 637 African SARS-CoV-2 variant 501Y.V2: A case report Reinfected hamsters were swabbed at 3 DPR and 5 DPR to 711 monitor shedding and necropsied at 5 DPR to determine lung viral load and pathology. To save 712 animals, Group 2 hamsters (n=9) from the homologous reinfection study (Figures 2 and 3) also 713 served as homologous reinfection controls for the heterologous reinfection study IgG antibody titers were assessed using an in-house ELISA against the WA1 spike protein IgG antibody titers were determined using an in-house ELISA assay specific to the RBD of the 717 WA1 spike protein. (D) WA1 neutralizing antibody titers were determined through a dilution 718 series using serum from either the WA1 Statistical analyses were 720 performed using nonparametric one-way AVOVA (Kruskal-Wallis) with correction for multiple 721 comparisons in Prism Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining were used to 726 assess histopathology and SARS-CoV-2 antigen distribution in lung tissue (E). (A) Viral RNA in 727 oral swabs. (B) Infectious virus in oral swabs. (C) Viral RNA levels in lung samples. (D) Infectious 728 virus in lung samples. (E) Histology and SARS-CoV-2 antigen distribution in lung tissue DPI) and 5 days after heterologous reinfection (54 DPI/5DPR). H&E (left panels) showed 731 resolving interstitial pneumonia developing into alveolar bronchiolization. Reinfection failed to acute SARS-CoV-2 infection (H&E IHC (right panels) showed that resolving interstitial pneumonia and alveolar bronchiolization 734 were not associated with SARS-CoV-2 immunoreactivity. Reinfection failed to result in SARS-735 A 736 nonparametric one-way AVOVA (Kruskal-Wallis) with correction for multiple comparisons was 737 used to determine statistical differences in PRISM. WA1 reinfection (blue SARS-CoV-2 isolate SARS-CoV-2/human/USA/ CDC Atlanta Genbank Accession MN985325 SARS-CoV-2 isolate nCoV-hCoV-19/USA/ Andy Pekosz GISAID # EPI_ISL_890360 MD-HP01542/2021 (B.1.351; SA; beta) SARS-CoV-2_2hCOV_19_England_204820464_ BEI Resources GISAID # EPI_ISL_683466 SARS-CoV-2 isolate nCoV-hCoV-19/USA/ Andy Pekosz GISAID # EPI_ISL_890360 MD-HP01542/2021 (B.1.351; SA; beta) SARS-CoV-2_2hCOV_19_England_204820464_ BEI Resources GISAID # EPI_ISL_683466 ChromoMap DAB kit Roche Tissue Diagnostics Graphpad https://www.graphpad.com/scientificsoftware/prism/